Compare LOAN & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOAN | COCH |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Real Estate Investment Trusts | Blank Checks |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 47.1M |
| IPO Year | 1999 | N/A |
| Metric | LOAN | COCH |
|---|---|---|
| Price | $4.28 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 26.0K | ★ 118.1K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $8,666,307.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.13 | $0.36 |
| 52 Week High | $5.85 | $1.91 |
| Indicator | LOAN | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 42.60 |
| Support Level | $4.26 | $0.63 |
| Resistance Level | $4.45 | $0.73 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 20.82 | 17.62 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.